Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Pharma
Travere's bid to gain new approval for Filspari hits FDA hitch
After asking for additional information on the drug's clinical benefit a few weeks ago, the FDA has delayed its decision on Filspari to treat FSGS.
Kevin Dunleavy
Jan 14, 2026 11:22am
Hansa's bid to push imlifidase into autoimmune indication flops
Dec 17, 2025 10:11am
Otsuka wins FDA nod in ever-more-crowded kidney disease space
Nov 26, 2025 11:10am
Hansa eyes FDA filing after ph. 3 win for kidney transplant med
Sep 25, 2025 12:37pm
Apellis snatches broad kidney disease expansion for Empaveli
Jul 28, 2025 8:00pm
Sobi places $300M bet on Empaveli in partnership with Apellis
Jul 1, 2025 11:28am
